Acute myelogenous leukemia
Conditions
Interventions
Idabicin combined with cytarabine low dose chemotherapy regimen group:Nil
Sponsors
Department of Hematology, Shanxi Provincial Cancer Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Male or female, aged 60 to 85 years; 2.According to the Us National Comprehensive Cancer Network (NCCN) acute myeloid leukemia clinical; Practice Guideline (2020.v3) criteria for patients with newly histopathologically confirmed AML(except M3) and with CR after 1-2 courses of induction therapy (including mdS-transformed AML patients); 3.Comply with AML diagnosis, including any of the following conditions: (1)Patients with CGA score of unfit; (2)Patients with CGA score of fit and PS score of 1-3; (3)Other patients with CGA score of fit who wish to receive low-dose chemotherapy; 4.Can tolerate chemotherapy regimens; 5.Understand and voluntarily sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with malignant tumors of other organs; 2.Abnormal liver and kidney function, total bilirubin level, serum creatinine level more than 2 times of the upper limit of normal value (ULN), aspartate aminotransferase (AST), alanine aminotransferase (ALT) more than 3 times of ULN (except AML); 3.Patients previously with severe heart disease, including myocardial infarction, grade 3-4 heart insufficiency, congestive heart failure requiring treatment, or left ventricular systolic ejection fraction below the normal range; 4.Patients with uncontrolled infection, or are currently receiving intravenous antibiotic therapy, except preventive antibiotics, antiviral and antifungal infection treatments; 5.Patients can not be enrolled which will be judged by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 years disease free survival ; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2 year overall survival;The incidence of grade 3-4 hematologic and non-hematologic adverse drug reactions; | — |
Countries
China
Contacts
Public ContactSu Liping
Shanxi Provincial Cancer Hospital
Outcome results
None listed